NOVO — Januar 2026
-
Hansen og Larsen analyserer sølvets eksplosion og Japan-risikoen før en spændende uge med C25-regnskaber fra bl.a. DSV, Mærsk og Vestas. Få svaret på, om Novo Nordisk er undervurderet i forhold til Eli Lilly baseret på nye data fra læger vs. analytikere. Bliv klar til 2026-markedets største bevægelser i denne uges afsnit af Investeringspodcasten. https://proinvestor.com/boards/130868
-
Novo Nordisk får sænket kursmål til 486 kr. fra 520 kr. hos Nordea: 2026-prognose er i fokus https://proinvestor.com/investornyt/1408254/novo-nordisk-far-saenket-kursmal-til-486-kr-fra-520-kr-hos-nordea-2026-prognose-er-i-fokus
-
Novos udbredelse af Wegovy på pilleform går bedre end ventet påpeger Danske Bank https://proinvestor.com/investornyt/1408264/novos-udbredelse-af-wegovy-pa-pilleform-gar-bedre-end-ventet-papeger-danske-bank
-
Aktiemarkedet befinder sig i et limbo forud for næste uge, hvor regnskaberne vælter ind. Det er urolige tider, og det ses bl.a. i de stigende guld- og sølvpriser. Også at Novo falder tilbage forud for regnskabet, efter kursen ellers var kommet ind i en positiv trend. Helge Larsen er spændt på, hvad uroen fra især USA betyder for guidingen fra Novo og resten af C25. Kort video: https://proinvestor.com/boards/130876
-
Novo får grønt lys til retssag mod kopist for falsk reklame, skriver Børsen https://borsen.dk/nyheder/virksomheder/novo-far-gront-lys-til-retssag-mod-kopist-for-falsk-reklame?b_source=borsen&b_medium=row_-1&b_campaign=latest_news_4
-
$NVO has been cleared by a US federal judge to proceed with a lawsuit against a telehealth company accused of false advertising.
Novo alleges that online pharmacy LifeRxMD misleadingly promoted compounded weight-loss products as equivalent to Ozempic, Wegovy, and Rybelsus, causing consumer confusion and harming Novo’s reputation. A New Jersey judge ruled the case can move forward.
-
ResearchPulse
@ResearchPulse1
·What to expect from week 3 wegovy pill sales.
Once again, the obesity spaces will be looking for new data tomorrow on how wegovy pill sales goes.
TRx data from Symphony will be released between 8-9 AM CET. Just before the Danish stock exchange opens at 9 AM.
Later at 12 CET -
Novo Nordisk: Det er fredag og "recepttid" https://proinvestor.com/boards/130890
-
New U.S. prescriptions for $NVO 's Wegovy pill are ramping fast: from 4,289 in week 1 to 20,371 in week 2, and now 26,763 in the latest week after launch.
-
Kilde: Investseekers
-
Novo Nordisks vægttabspille fortsætter positiv udvikling mener AL Sydbank https://proinvestor.com/investornyt/1408801/novo-nordisks-vaegttabspille-fortsaetter-positiv-udvikling-mener-al-sydbank
-
Investseekers
@investseekers
·
3 t
A comparison for $NVO 's oral Wegovy vs Wegovy injection and $LLY 's Zepbound after launch:New prescriptions jumped:
4,289 → 20,371 → 26,763 in the first three weeks.
For comparison (same weeks):
• Wegovy injection: 174 → 1,017 → 1,925
• Zepbound (Eli Lilly): 1,909 → 10,026 → 20,133
Insured patients only (Symphony data).
-
Jyske Bank has lowered its price target on $NVO shares to DKK 460 from DKK 475, while maintaining its “buy” recommendation.
-
Er der nogen der ved hvor længe en udskreven recept dækker ? Interesseret i at vide hvornår vi ser recepter komme ande gang.
-
$NVO US prescriptions for Novo Nordisk's wegovy pill were 26,109 for week ended Jan 23, IQVIA data shows
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind